These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

855 related articles for article (PubMed ID: 30274202)

  • 21. HCV-Induced Epigenetic Changes Associated With Liver Cancer Risk Persist After Sustained Virologic Response.
    Hamdane N; Jühling F; Crouchet E; El Saghire H; Thumann C; Oudot MA; Bandiera S; Saviano A; Ponsolles C; Roca Suarez AA; Li S; Fujiwara N; Ono A; Davidson I; Bardeesy N; Schmidl C; Bock C; Schuster C; Lupberger J; Habersetzer F; Doffoël M; Piardi T; Sommacale D; Imamura M; Uchida T; Ohdan H; Aikata H; Chayama K; Boldanova T; Pessaux P; Fuchs BC; Hoshida Y; Zeisel MB; Duong FHT; Baumert TF
    Gastroenterology; 2019 Jun; 156(8):2313-2329.e7. PubMed ID: 30836093
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dynamic noninvasive markers predict hepatocellular carcinoma in chronic hepatitis C patients without sustained virological response after interferon-based therapy: Prioritize who needs urgent direct-acting antiviral agents.
    Huang CM; Hu TH; Chang KC; Tseng PL; Lu SN; Chen CH; Wang JH; Lee CM; Tsai MC; Lin MT; Yen YH; Hung CH; Cho CL; Wu CK
    Medicine (Baltimore); 2017 Nov; 96(46):e8696. PubMed ID: 29145306
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hepatocellular Carcinoma after Achievement of Sustained Viral Response with Daclatasvir and Asunaprevir in Patients with Chronic Hepatitis C Virus Infection.
    Ida H; Hagiwara S; Kono M; Minami T; Chishina H; Arizumi T; Takita M; Yada N; Minami Y; Ueshima K; Nishida N; Kudo M
    Dig Dis; 2017; 35(6):565-573. PubMed ID: 29040989
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hepatocellular carcinoma risk following direct-acting antiviral HCV therapy: A systematic review, meta-analyses, and meta-regression.
    Waziry R; Hajarizadeh B; Grebely J; Amin J; Law M; Danta M; George J; Dore GJ
    J Hepatol; 2017 Dec; 67(6):1204-1212. PubMed ID: 28802876
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Hepatitis C virus-induced hepatocellular carcinoma: a narrative review.
    Ružić M; Pellicano R; Fabri M; Luzza F; Boccuto L; Brkić S; Abenavoli L
    Panminerva Med; 2018 Dec; 60(4):185-191. PubMed ID: 29856183
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Improved survival of patients with hepatocellular carcinoma and compensated hepatitis C virus-related cirrhosis who attained sustained virological response.
    Bruno S; Di Marco V; Iavarone M; Roffi L; Boccaccio V; Crosignani A; Cabibbo G; Rossi S; Calvaruso V; Aghemo A; Giacomelli L; Craxì A; Colombo M; Maisonneuve P
    Liver Int; 2017 Oct; 37(10):1526-1534. PubMed ID: 28418617
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The influence of direct-acting antivirals in hepatitis C virus related hepatocellular carcinoma after curative treatment.
    Kuo YH; Wang JH; Chang KC; Hung CH; Lu SN; Hu TH; Yen YH; Kee KM; Chen CH
    Invest New Drugs; 2020 Feb; 38(1):202-210. PubMed ID: 31701431
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Hepatocellular carcinoma incidence post direct-acting antivirals in hepatitis C-related advanced fibrosis/cirrhosis patients in Australia.
    Chan PPY; Levy MT; Shackel N; Davison SA; Prakoso E
    Hepatobiliary Pancreat Dis Int; 2020 Dec; 19(6):541-546. PubMed ID: 32660841
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Genome-Wide Association Study Identifies TLL1 Variant Associated With Development of Hepatocellular Carcinoma After Eradication of Hepatitis C Virus Infection.
    Matsuura K; Sawai H; Ikeo K; Ogawa S; Iio E; Isogawa M; Shimada N; Komori A; Toyoda H; Kumada T; Namisaki T; Yoshiji H; Sakamoto N; Nakagawa M; Asahina Y; Kurosaki M; Izumi N; Enomoto N; Kusakabe A; Kajiwara E; Itoh Y; Ide T; Tamori A; Matsubara M; Kawada N; Shirabe K; Tomita E; Honda M; Kaneko S; Nishina S; Suetsugu A; Hiasa Y; Watanabe H; Genda T; Sakaida I; Nishiguchi S; Takaguchi K; Tanaka E; Sugihara J; Shimada M; Kondo Y; Kawai Y; Kojima K; Nagasaki M; Tokunaga K; Tanaka Y;
    Gastroenterology; 2017 May; 152(6):1383-1394. PubMed ID: 28163062
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Late development of hepatocellular carcinoma after viral clearance in patients with chronic hepatitis C: A need for continual surveillance.
    Tong MJ; Theodoro CF; Salvo RT
    J Dig Dis; 2018 Jul; 19(7):411-420. PubMed ID: 29889353
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Risk of hepatocellular carcinoma and fibrosis evolution in hepatitis C patients with severe fibrosis or cirrhosis treated with direct acting antiviral agents.
    Hamoir C; Horsmans Y; Stärkel P; Dahlqvist G; Negrin Dastis S; Lanthier N
    Acta Gastroenterol Belg; 2021; 84(1):25-32. PubMed ID: 33639690
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Follow-up of sustained virological responders with hepatitis C and advanced liver disease after interferon/ribavirin-free treatment.
    Kozbial K; Moser S; Al-Zoairy R; Schwarzer R; Datz C; Stauber R; Laferl H; Strasser M; Beinhardt S; Stättermayer AF; Gschwantler M; Zoller H; Maieron A; Graziadei I; Trauner M; Steindl-Munda P; Hofer H; Ferenci P
    Liver Int; 2018 Jun; 38(6):1028-1035. PubMed ID: 29136329
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Does interferon-free direct-acting antiviral therapy for hepatitis C after curative treatment for hepatocellular carcinoma lead to unexpected recurrences of HCC? A multicenter study by the Japanese Red Cross Hospital Liver Study Group.
    Mashiba T; Joko K; Kurosaki M; Ochi H; Osaki Y; Kojima Y; Nakata R; Goto T; Takehiro A; Kimura H; Mitsuda A; Kawanami C; Uchida Y; Ogawa C; Kusakabe A; Narita R; Ide Y; Abe T; Tsuji K; Kitamura T; Okada K; Sohda T; Shigeno M; Satou T; Izumi N
    PLoS One; 2018; 13(4):e0194704. PubMed ID: 29659591
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Reduction of the Risk of Hepatocellular Carcinoma over Time Using Direct-Acting Antivirals: A Propensity Score Analysis of a Real-Life Cohort (PITER HCV).
    Quaranta MG; Cavalletto L; Russo FP; Calvaruso V; Ferrigno L; Zanetto A; Mattioli B; D'Ambrosio R; Panetta V; Brancaccio G; Raimondo G; Brunetto MR; Zignego AL; Coppola C; Iannone A; Biliotti E; Rosselli Del Turco E; Massari M; Licata A; Barbaro F; Persico M; Morisco F; Pompili M; Cerini F; Puoti M; Santantonio T; Craxì A; Kondili LA; Chemello L; On Behalf Of Piter Collaborating Investigators
    Viruses; 2024 Apr; 16(5):. PubMed ID: 38793565
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Risk of Hepatocellular Cancer Recurrence in Hepatitis C Virus+ Patients Treated with Direct-Acting Antiviral Agents.
    Zou WY; Choi K; Kramer JR; Yu X; Cao Y; El-Serag HB; Kanwal F
    Dig Dis Sci; 2019 Nov; 64(11):3328-3336. PubMed ID: 31041639
    [TBL] [Abstract][Full Text] [Related]  

  • 36. AGA Clinical Practice Update on Interaction Between Oral Direct-Acting Antivirals for Chronic Hepatitis C Infection and Hepatocellular Carcinoma: Expert Review.
    Singal AG; Lim JK; Kanwal F
    Gastroenterology; 2019 Jun; 156(8):2149-2157. PubMed ID: 30878469
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Newly diagnosed hepatocellular carcinoma in patients with advanced hepatitis C treated with DAAs: A prospective population study.
    Romano A; Angeli P; Piovesan S; Noventa F; Anastassopoulos G; Chemello L; Cavalletto L; Gambato M; Russo FP; Burra P; Vincenzi V; Scotton PG; Panese S; Tempesta D; Bertin T; Carrara M; Carlotto A; Capra F; Carolo G; Scroccaro G; Alberti A
    J Hepatol; 2018 Aug; 69(2):345-352. PubMed ID: 29551707
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prediction of the Risk of Hepatocellular Carcinoma in Chronic Hepatitis C Patients after Sustained Virological Response by Aspartate Aminotransferase to Platelet Ratio Index.
    Lee K; Sinn DH; Gwak GY; Cho HC; Jung SH; Paik YH; Choi MS; Lee JH; Koh KC; Paik SW
    Gut Liver; 2016 Sep; 10(5):796-802. PubMed ID: 27114418
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Hepatocellular carcinoma decreases the chance of successful hepatitis C virus therapy with direct-acting antivirals.
    Prenner SB; VanWagner LB; Flamm SL; Salem R; Lewandowski RJ; Kulik L
    J Hepatol; 2017 Jun; 66(6):1173-1181. PubMed ID: 28161470
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Should surveillance for liver cancer be modified in hepatitis C patients after treatment-related cirrhosis regression?
    D'Ambrosio R; Colombo M
    Liver Int; 2016 Jun; 36(6):783-90. PubMed ID: 26936383
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 43.